



May 3, 2017

## **Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017**

REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., May 03, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will report its first quarter 2017 financial results and provide a clinical update on May 9, 2017. In conjunction with this announcement, Ocera will host a conference call and live audio webcast on May 9, 2017 at 4:30 p.m. Eastern Time to both review the financial results and provide an update on its clinical development programs of OCR-002 for the treatment of hepatic encephalopathy (HE), a debilitating liver disorder and significant burden on the healthcare system.

The audio webcast can be accessed under "Presentations & Events" in the Investor Relations section of the Company's website at [www.ocerainc.com](http://www.ocerainc.com).

Domestic investors wishing to participate in the call should dial (844) 419-1758 and international investors should dial (209) 905-5955. The conference ID is 17133971. Investors can also access the call at <http://edge.media-server.com/m/p/mkgjs75d>.

Replays of the call will be available on the Company's website through June 9, 2017. Domestic investors can access the replay by dialing (844) 419-1758 and international investors can access the replay by dialing (209) 905-5955. The conference ID to access the reply is 17133971.

### **About Ocera**

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please visit [www.ocerainc.com](http://www.ocerainc.com).

Susan Sharpe  
Ocera Therapeutics, Inc.  
[contact@ocerainc.com](mailto:contact@ocerainc.com)  
919-328-1109